E. Rand Sutherland compensation by year
Upstream Bio Summary Compensation Table · all 2 fiscal years held| Component | FY2024 | FY2025 |
|---|---|---|
| Salary | $407,955 | $650,000 |
| Bonus | $0 | $0 |
| Stock awards | $0 | $0 |
| Option awards | $8,375,648 | $3,300,350 |
| Non-equity incentive | $315,000 | $341,250 |
| Pension and deferred compensation | $0 | $0 |
| All other | $10,350 | $10,500 |
| Total | $9,108,953 | $4,302,100 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Upstream Bio, Inc. DEF 14A filed April 16, 2026, accession 0001193125-26-158966, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Upstream Bio, Inc. filed document, accession 0001193125-26-158966. Every figure is read from that document and cited to the page and table it appears in. Filed April 16, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 505,578 | — | $5.69 |
| Option | 614,717 | — | $6.59 |
| Option | 395,834 | — | $8.53 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Upstream Bio, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
2 Form 4 lines since the FY2025 proxy (filed April 16, 2026)current to 2026-11-06 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-16 | Sale | — | 2,095 | $5.49 | 68,717 |
| 2026-06-16 | Sale | — | 2,095 | $6.10 | 70,812 |
The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Upstream Bio’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| E. Rand Sutherland · this page | Chief Executive Officer | $4,302,100 |
| Michael Paul Gray | Chief Financial Officer and Chief Operating Officer | $1,993,437 |
| Aaron Deykin | Chief Medical Officer and Head of Research and Development | $1,830,916 |
Board service
Upstream Bio board · FY2025How this board is paid
Company policy: Upstream Bio pays directors a $40,000 cash retainer. As stated in Upstream Bio's FY2025 proxy.
The full Upstream Bio compensation record
free company briefThis page is one person within Upstream Bio's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Upstream Bio's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Upstream Bio's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order UPB
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.